Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Positive data for Eli Lilly drug in non-Hodgkin’s lymphoma
The data presented at the American Society of Hematology 47th Annual Meeting and Exposition in Atlanta, Georgia, showed that the drug, enzastaurin, slowed the progression of diffuse large
The data presented at the American Society of Hematology 47th Annual Meeting and Exposition in Atlanta, Georgia, showed that the drug, enzastaurin, slowed the progression of diffuse large
Although PTI-901 demonstrated meaningful relief of symptoms in the second month of treatment, the drug did not demonstrate a meaningful benefit in the third month of treatment, which
Tykerb is an orally bio-available small molecule which potently inhibits, two receptors, ErbB2 and ErbB1, and is currently in development as a first-line treatment for ErbB2-overexpressing breast cancer.
Teva’s license in the US will become effective in October 2011 unless there is a pediatric extension for the drug, which would delay the entry date by six
34 adult patients with documented CD20-positive B-cell non-Hodgkin’s lymphoma were enrolled and were infused once weekly for four weeks consecutively with 120, 200, 375, or 750 mg/m2 of
Atrial fibrillation can cause the affected part of the heart to stop pumping blood properly and can bring on serious conditions such as angina and stroke. The dose-ranging
“If approved by the FDA, we believe Sebazole will provide significant patient benefits in the non-steroidal management of seborrheic dermatitis, with less risk for irritation and a more
The anti-inflammatory effects of QR-442 were first evaluated in in-vitro experiments as well as in an immune-mediated inflammation model in mice. In the mouse model, inflammation of the
“Trasylol has been proven safe and effective in reducing blood loss and transfusion requirements in coronary artery bypass surgery, and we are studying the drug to determine if
The transaction is part of GSK’s strategic initiative to expand its vaccine research and production network in North America, and adds to the company’s recent acquisitions of Corixa